As a Free StocksGuide user, you can view scores for all 7,040 stocks worldwide.
13 Analysts have issued a Lineage Cell Therapeutics forecast:
13 Analysts have issued a Lineage Cell Therapeutics forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 11 11 |
76%
76%
|
|
| Gross Profit | 11 11 |
90%
90%
|
|
| EBITDA | -20 -20 |
21%
21%
|
|
| EBIT (Operating Income) EBIT | -20 -20 |
20%
20%
|
|
| Net Profit | -41 -41 |
69%
69%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 70 full-time employees. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, it designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.
| Head office | United States |
| Employees | 74 |
| Website | lineagecell.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


